

Larouche ValÃ©rie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7072353/publications.pdf>

Version: 2024-02-01

19
papers

2,153
citations

687363

13
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

4778
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. <i>Journal of Clinical Oncology</i> , 2016, 34, 2206-2211.	1.6	692
2	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	28.9	596
3	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 2934-2941.	1.6	232
4	Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3537-3543.	1.6	157
5	Stalled developmental programs at the root of pediatric brain tumors. <i>Nature Genetics</i> , 2019, 51, 1702-1713.	21.4	136
6	Tumors of the central nervous system in the first year of life. <i>Pediatric Blood and Cancer</i> , 2007, 49, 1074-1082.	1.5	55
7	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. <i>Nature Medicine</i> , 2022, 28, 125-135.	30.7	53
8	DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells. <i>Cancer Discovery</i> , 2021, 11, 1176-1191.	9.4	46
9	Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. <i>Journal of Neuro-Oncology</i> , 2017, 132, 155-162.	2.9	43
10	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. <i>Journal of Clinical Oncology</i> , 2021, 39, 2779-2790.	1.6	40
11	Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27389.	1.5	25
12	Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. <i>Journal of Clinical Oncology</i> , 2019, 37, 461-470.	1.6	23
13	Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. <i>JAMA Oncology</i> , 2021, 7, 1806.	7.1	22
14	Efficacy of Dabrafenib for three children with brainstem BRAFV600E positive ganglioglioma. <i>Journal of Neuro-Oncology</i> , 2019, 145, 135-141.	2.9	9
15	Characteristics of patients ≤ 10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, 24, 141-152.	1.2	9
16	Incidence of childhood cancer in Canada during the COVID-19 pandemic. <i>Cmaj</i> , 2021, 193, E1798-E1806.	2.0	6
17	Incidence trends in pediatric central nervous system tumors in Canada: a 15 years report from Cancer and Young People in Canada (CYP-C) registry. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa012.	0.7	5
18	Translating the Symptom Screening in Pediatrics Tool (SSPedi) into French and among French-speaking children receiving cancer treatments, evaluating understandability and cultural relevance in a multiple-phase descriptive study. <i>BMJ Open</i> , 2020, 10, e035265.	1.9	4

#	ARTICLE	IF	CITATIONS
19	Screening for asymptomatic diabetes and metabolic comorbidities in pediatric patients during therapy for acute lymphoblastic leukemia. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2021, 34, 627-632.	0.9	0